Redeye retains its positive view on Transtema following a solid Q3 report, showing high organic and acquired growth and healthy margins. While demand is strong, cost inflation puts pressure on Transtema’s operations, but management seems confident its margin target can be maintained. We raise our forecasts slightly and leave our Base Case unchanged.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

Transtema - Strong Growth Momentum and Healthy Margins

© Modular Finance, source Nordic Press Releases